echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Hengrui Medicine and Iktos of France reached a strategic cooperation on AI new drug R&D platform

    Hengrui Medicine and Iktos of France reached a strategic cooperation on AI new drug R&D platform

    • Last Update: 2021-12-30
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Recently, Hengrui Medicine and Iktos of France signed a strategic cooperation agreement on AI new drug development platform


    Makya™ developed by Iktos is an artificial intelligence-driven generative de novo small molecule drug design software that can be used for multi-parameter optimization (MPO)


    Dr.


    "We are very happy to cooperate with Hengrui, a leading global pharmaceutical company from China


    Founded in October 2016, Iktos is a start-up company specializing in the development of artificial intelligence solutions for medicinal chemistry and new drug design


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.